Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $7,000,000.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 200,000 shares of the company’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $35.00, for a total value of $7,000,000.00. Following the completion of the transaction, the director directly owned 115,167 shares of the company’s stock, valued at approximately $4,030,845. This trade represents a 63.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88.
• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total value of $241,424.40.

Pharvaris Stock Performance

Shares of NASDAQ PHVS traded down $0.35 during midday trading on Monday, reaching $36.02. 653,689 shares of the stock were exchanged, compared to its average volume of 412,750. The company has a 50 day simple moving average of $35.37 and a 200 day simple moving average of $31.75. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $43.25. The stock has a market capitalization of $2.36 billion, a P/E ratio of -11.81 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, research analysts expect that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

Several institutional investors have recently added to or reduced their stakes in the business. venBio Partners LLC acquired a new position in Pharvaris in the 2nd quarter worth about $160,569,809. Wellington Management Group LLP grew its position in Pharvaris by 12.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after purchasing an additional 274,034 shares during the last quarter. Commodore Capital LP raised its holdings in Pharvaris by 1.6% during the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after purchasing an additional 29,525 shares during the last quarter. 5AM Venture Management LLC acquired a new stake in Pharvaris in the 2nd quarter worth about $27,581,008. Finally, Seven Fleet Capital Management LP increased its position in shares of Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after acquiring an additional 457,804 shares in the last quarter.

Analysts Set New Price Targets

PHVS has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Oppenheimer restated an “outperform” rating and set a $75.00 price objective on shares of Pharvaris in a report on Tuesday, September 8th. Wedbush upped their price target on shares of Pharvaris from $42.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a report on Wednesday, September 9th. Finally, UBS Group set a $79.00 target price on shares of Pharvaris in a research report on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pharvaris has a consensus rating of “Moderate Buy” and a consensus target price of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.